Spinal Muscular Atrophy Treatment Market By Type (Type I Spinal Muscular Atrophy, Type II Spinal Muscular Atrophy, Type III Spinal Muscular Atrophy), By Application (Gene Therapy, Drugs) - Growth, Future Prospects, And Competitive Landscape, 2019-2027

During the forecast period, the spinal muscular atrophy treatment market will exhibit dynamic growth.

The global spinal muscular atrophy treatment market is growing proficiently and is expected to grow at a CAGR of 14.5%. Globally, the increasing incidence of SMA, along with improved treatment management through innovative gene therapy and drugs, will drive the growth of the market. Increasing awareness, FDA approval for new drugs, partnerships for enhanced R&D, and private funding will boost the overall demand for SMA treatment on a global scale.

Market Synopsis

Type I SMA treatment to witness a significant CAGR.

Growing hospital admissions for type I SMA and its therapeutic reatment generated the largest revenue share in 2018. Increasing incidences of SMA in infants and advancements in gene therapy, along with strong pipeline drugs internationally, will drive the market's growth. New drug development for type II and III will show promising growth in the near future. Enhanced joint development programs for innovative therapies will drive the demand in the near future, such as Risdiplam (RG7916), reldesemtiv (CK-2127107), Branaplam (LMI070), and others.

Gene therapy treatment is expected to witness a significant CAGR in the near future.

Drugs accounted for the maximum revenue share in 2018. In 2018, drugs emerged as the principal treatment application for spinal muscular atrophy (SMA) since Spinraza (developed by Biogen and Ionis Pharmaceuticals) is the only drug approved to date. Additionally, in May 2019, the U.S. FDA approved Zolgensma® (onasemnogene abeparvovec-xiii) by AveXis (Novartis AG), the first gene therapy for infants (less than two years of age) suffering from spinal muscular atrophy.

Advancements in gene therapy, FDA approval of new drugs, and strong pipeline products offer a huge advantage in the global SMA treatment market. If PTC Therapeutics and F. Hoffmann-La Roche AG proceeded with official plans to file for approval in the U.S. market and Europe by the end of 2019, it would set a possible approval date for the SMA treatment in the first half of 2020.

Increased research and development with strong product pipelines in the developed regions

Major players in the spinal muscular atrophy treatment market are Biogen Idec, Pfizer Inc., Boehringer Ingelheim, Isis Pharmaceuticals, F. Hoffmann-La Roche, Regeneron Pharmaceuticals, AveXis Inc., Novartis AG, and others.

Mergers and acquisitions, partnerships, and improved R&D on targeted treatments for spinal muscular atrophy will further drive the overall market's growth in the near future. Strong pipeline drugs will enhance the overall treatment management for SMA, such as Zolgensma (Novartis), Branaplam (Novartis), Amifampridine Phosphate (Catalyst Pharmaceuticals), Risdiplam (Hoffmann-La Roche), and others.

Historical and Forecast Period

This study report includes an analysis of each segment from 2017 to 2027, with 2018 as the base year. The compound annual growth rate (CAGR) for each of the respective segments is estimated for the forecast period from 2019 to 2027.

Report Scope by Segments

Market Segmentation

The current report also encompasses qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints, and opportunities that give a better understanding of the overall spinal muscular atrophy treatment market. Additionally, the global report also comprises a graphical representation of the competitive landscape based on their market initiatives and strategies, product portfolios, and business strengths.

Key questions are answered in this report.

• What are the current market trends and dynamics in the spinal muscular atrophy treatment market, and what are the valuable opportunities for emerging players?
• Which segment accounts for the fastest CAGR during the forecast period?
• Which type of segment holds a larger market share and why?
• Are low- and middle-income economies investing in the spinal muscular atrophy treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and the Middle East and Africa?

 Frequently Asked Question: